癌症。一项风险业务——评估乳腺癌风险。 - Suppr

Suppr

超能文献

Cancer. A risky business--assessing breast cancer risk.

作者信息

Levy-Lahad Ephrat, Plon Sharon E

机构信息

Medical Genetics Unit, Shaare Zedek Medical Center, Hebrew University, Jerusalem 91031, Israel.

出版信息

Science. 2003 Oct 24;302(5645):574-5. doi: 10.1126/science.1091465.

DOI:10.1126/science.1091465

PMID:14576407

Abstract

摘要

相似文献

Cancer. A risky business--assessing breast cancer risk.

Science. 2003 Oct 24;302(5645):574-5. doi: 10.1126/science.1091465.

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.

Science. 2003 Oct 24;302(5645):643-6. doi: 10.1126/science.1088759.

Breast cancer risks for BRCA1/2 carriers.

Science. 2004 Dec 24;306(5705):2187-91; author reply 2187-91.

Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.

Breast Cancer Res Treat. 2006 Jan;95(1):81-7. doi: 10.1007/s10549-005-9047-1. Epub 2005 Oct 27.

Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.

J Natl Cancer Inst. 2005 Sep 21;97(18):1382-4. doi: 10.1093/jnci/dji281.

One risk fits all?

J Clin Oncol. 2007 Aug 1;25(22):3383-4; author reply 3384. doi: 10.1200/JCO.2007.12.3489.

Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.

Am J Obstet Gynecol. 2007 Apr;196(4):e6-9. doi: 10.1016/j.ajog.2007.01.026.

Genomic rearrangements in the BRCA1 and BRCA2 genes.

Hum Mutat. 2005 May;25(5):415-22. doi: 10.1002/humu.20169.

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.

Am Fam Physician. 2006 Nov 15;74(10):1759-60.

Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.

J Med Genet. 2005 Mar;42(3):e20. doi: 10.1136/jmg.2004.027243.

引用本文的文献

A unified analytic framework for prioritization of non-coding variants of uncertain significance in heritable breast and ovarian cancer.

BMC Med Genomics. 2016 Apr 11;9:19. doi: 10.1186/s12920-016-0178-5.

N-Methyl-N-nitrosourea as a mammary carcinogenic agent.

Tumour Biol. 2015 Dec;36(12):9095-117. doi: 10.1007/s13277-015-3973-2. Epub 2015 Sep 19.

BRCA1/2 population screening: embracing the benefits.

Curr Oncol. 2015 Aug;22(4):e230-1. doi: 10.3747/co.22.2660.

Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.

Mutat Res. 2009 Jan 15;660(1-2):1-11. doi: 10.1016/j.mrfmmm.2008.09.017. Epub 2008 Oct 17.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Cancer. A risky business--assessing breast cancer risk.

Science. 2003 Oct 24;302(5645):574-5. doi: 10.1126/science.1091465.

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.

Science. 2003 Oct 24;302(5645):643-6. doi: 10.1126/science.1088759.

Breast cancer risks for BRCA1/2 carriers.

Science. 2004 Dec 24;306(5705):2187-91; author reply 2187-91.

Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.

Breast Cancer Res Treat. 2006 Jan;95(1):81-7. doi: 10.1007/s10549-005-9047-1. Epub 2005 Oct 27.

Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.

J Natl Cancer Inst. 2005 Sep 21;97(18):1382-4. doi: 10.1093/jnci/dji281.

One risk fits all?

J Clin Oncol. 2007 Aug 1;25(22):3383-4; author reply 3384. doi: 10.1200/JCO.2007.12.3489.

Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.

Am J Obstet Gynecol. 2007 Apr;196(4):e6-9. doi: 10.1016/j.ajog.2007.01.026.

Genomic rearrangements in the BRCA1 and BRCA2 genes.

Hum Mutat. 2005 May;25(5):415-22. doi: 10.1002/humu.20169.

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.

Am Fam Physician. 2006 Nov 15;74(10):1759-60.

Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.

J Med Genet. 2005 Mar;42(3):e20. doi: 10.1136/jmg.2004.027243.

引用本文的文献

A unified analytic framework for prioritization of non-coding variants of uncertain significance in heritable breast and ovarian cancer.

BMC Med Genomics. 2016 Apr 11;9:19. doi: 10.1186/s12920-016-0178-5.

N-Methyl-N-nitrosourea as a mammary carcinogenic agent.

Tumour Biol. 2015 Dec;36(12):9095-117. doi: 10.1007/s13277-015-3973-2. Epub 2015 Sep 19.

BRCA1/2 population screening: embracing the benefits.

Curr Oncol. 2015 Aug;22(4):e230-1. doi: 10.3747/co.22.2660.

Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.

Mutat Res. 2009 Jan 15;660(1-2):1-11. doi: 10.1016/j.mrfmmm.2008.09.017. Epub 2008 Oct 17.